Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

View:
Post by biggdogg on Dec 14, 2023 11:53am

sales

This is good news, for a distribution company to sign a deal with Voy means their product launch is imminent, no one signs a deal unless they know they are going to be supplied. There will now be many distribution companies signing deals in the future. They must be close to getting all 5 products tested and ready for market. The set back with the FDA of change of classification to a drug, in February of this year, will not stop them from moving forward. The monopoly will have two choices, loose market share or buy them out. What happens to the monopoly when customers switch to Voyageur barium? They no longer buy any of their other products such as iodine and gadolinium. Losing barium customers has a much deeper impact on the monopoly than just barium sales. Go Voyageur! Get more deals in place, this is what we have been waiting for!!
Comment by whitenorth72 on Dec 14, 2023 3:23pm
When the first official deal is secured this will merit their business plan and the PEA takes hold. FDA approval should follow when funds are secured because Barium is a Critical mineral in the states. Canada has dropped the ball by not including this mineral (probably because it didn't fit in the maple leaf design) but will soon regret it if a buyout does become a reality.
Comment by WarrantOfficer on Dec 15, 2023 9:24am
I agree 100% biggdogg The Barium is the beginning. Put up or buy out in the future for the monoply. I was looking at the countries in Central America. Not the safest countries in the world, but every country has it's do not go to areas. Top three GDP Central American countries in 2022 1. Guatemala 2. Panama 3. Cosa Rica ......I completley understand the requiremnt for distributor discretion ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1